Department of Rheumatology and Immunology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, 637000, People's Republic of China.
Henry Ford Immunology Program, Departments of Dermatology and Internal Medicine, Henry Ford Health System, 1 Ford Place, Detroit, MI, 48202, USA.
Arthritis Res Ther. 2024 May 6;26(1):96. doi: 10.1186/s13075-024-03335-4.
Gout is caused by monosodium urate (MSU) crystals deposition to trigger immune response. A recent study suggested that inhibition of Class I Histone deacetylases (HDACs) can significantly reduce MSU crystals-induced inflammation. However, which one of HDACs members in response to MSU crystals was still unknown. Here, we investigated the roles of HDAC3 in MSU crystals-induced gouty inflammation.
Macrophage specific HDAC3 knockout (KO) mice were used to investigate inflammatory profiles of gout in mouse models in vivo, including ankle arthritis, foot pad arthritis and subcutaneous air pouch model. In the in vitro experiments, bone marrow-derived macrophages (BMDMs) from mice were treated with MSU crystals to assess cytokines, potential target gene and protein.
Deficiency of HDAC3 in macrophage not only reduced MSU-induced foot pad and ankle joint swelling but also decreased neutrophils trafficking and IL-1β release in air pouch models. In addition, the levels of inflammatory genes related to TLR2/4/NF-κB/IL-6/STAT3 signaling pathway were significantly decreased in BMDMs from HDAC3 KO mice after MSU treatment. Moreover, RGFP966, selective inhibitor of HDAC3, inhibited IL-6 and TNF-α production in BMDMs treated with MSU crystals. Besides, HDAC3 deficiency shifted gene expression from pro-inflammatory macrophage (M1) to anti-inflammatory macrophage (M2) in BMDMs after MSU challenge.
Deficiency of HDAC3 in macrophage alleviates MSU crystals-induced gouty inflammation through inhibition of TLR2/4 driven IL-6/STAT3 signaling pathway, suggesting that HDAC3 could contribute to a potential therapeutic target of gout.
痛风是由单钠尿酸盐(MSU)晶体沉积引发免疫反应导致的。最近的一项研究表明,抑制 I 类组蛋白去乙酰化酶(HDACs)可以显著减轻 MSU 晶体诱导的炎症。然而,针对 MSU 晶体,哪种 HDACs 成员起作用尚不清楚。在这里,我们研究了 HDAC3 在 MSU 晶体诱导的痛风性炎症中的作用。
使用巨噬细胞特异性 HDAC3 敲除(KO)小鼠,在体内小鼠模型中研究痛风的炎症特征,包括踝关节关节炎、足垫关节炎和皮下气囊模型。在体外实验中,用 MSU 晶体处理来自小鼠的骨髓来源巨噬细胞(BMDMs),以评估细胞因子、潜在靶基因和蛋白。
巨噬细胞中 HDAC3 的缺失不仅减少了 MSU 诱导的足垫和踝关节肿胀,还减少了气囊模型中的中性粒细胞迁移和 IL-1β释放。此外,在 MSU 处理后,HDAC3 KO 小鼠的 BMDMs 中与 TLR2/4/NF-κB/IL-6/STAT3 信号通路相关的炎症基因水平显著降低。此外,HDAC3 的选择性抑制剂 RGFP966 抑制了 MSU 晶体处理的 BMDMs 中 IL-6 和 TNF-α 的产生。此外,HDAC3 缺失使 BMDMs 在 MSU 刺激后从促炎型巨噬细胞(M1)向抗炎型巨噬细胞(M2)的基因表达发生转变。
巨噬细胞中 HDAC3 的缺失通过抑制 TLR2/4 驱动的 IL-6/STAT3 信号通路减轻 MSU 晶体诱导的痛风性炎症,表明 HDAC3 可能成为痛风的潜在治疗靶点。